Drug:
Reaction: PRODUCT DOSE OMISSION ISSUE
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25120987 |
CA |
1 | |
Device issue, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 402 | 25121027 |
US |
56 | 2 |
Product dose omission issue, |
||||
CABOTEGRAVIR, |
||||
| 403 | 25121033 |
IE |
42 | 2 |
Device defective, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 404 | 25121073 |
US |
62 | 1 |
Spinal disorder, Tooth disorder, Breast disorder, Sinus disorder, Arthralgia, Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 405 | 25121163 |
US |
2 | |
Loop electrosurgical excision procedure, Complication associated with device, Product dose omission issue, |
||||
ETONOGESTREL, ETONOGESTREL, |
||||
| 406 | 25121211 |
US |
48 | 2 |
Eosinophilic oesophagitis, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 407 | 25121244 |
US |
28 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 408 | 25121277 |
US |
58 | 2 |
Product dose omission issue, Device defective, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 409 | 25121333 |
US |
68 | 2 |
Product selection error, Product dose omission issue, |
||||
TALQUETAMAB, |
||||
| 410 | 25121390 |
US |
||
Hospitalisation, Symptom recurrence, Product dose omission issue, |
||||
BELIMUMAB, BELIMUMAB, BELIMUMAB, |
||||
| 411 | 25121430 |
US |
||
Hospitalisation, Product use issue, Product dose omission issue, Therapy interrupted, Circumstance or information capable of leading to medication error, |
||||
LOTILANER OPHTHALMIC SOLUTION, FENOFIBRATE, ROSUVASTATIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ATENOLOL, GLIMEPIRIDE, |
||||
| 412 | 25121436 |
US |
2 | |
Eczema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 413 | 25121489 |
US |
||
Dyspnoea, Fatigue, Decreased activity, Device issue, Product dose omission issue, Incorrect dose administered by device, Device delivery system issue, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 414 | 25121497 |
CA |
||
Product dose omission issue, Diabetic ketoacidosis, Product use issue, Inappropriate schedule of product administration, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, EMPAGLIFLOZIN, INSULIN LISPRO, INSULIN DEGLUDEC, |
||||
| 415 | 25121506 |
US |
2 | |
Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE, |
||||
| 416 | 25121566 |
US |
22 | 2 |
Product dose omission issue, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 417 | 25121720 |
US |
75 | |
Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 418 | 25121732 |
CA |
71 | |
Dizziness, Abdominal discomfort, Abdominal distension, Asthma, Dyspnoea, Dyspnoea exertional, Fatigue, Sleep apnoea syndrome, Loss of personal independence in daily activities, Product dose omission issue, Hospitalisation, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, MEPOLIZUMAB, MEPOLIZUMAB, MEPOLIZUMAB, MEPOLIZUMAB, ALBUTEROL SULFATE, |
||||
| 419 | 25121774 |
US |
2 | |
Influenza, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 420 | 25121779 |
US |
54 | 2 |
Product dose omission issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 421 | 25121783 |
US |
85 | 2 |
Product dose omission issue, |
||||
MAVACAMTEN, |
||||
| 422 | 25121789 |
US |
45 | 2 |
Product dose omission issue, Injection site bruising, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 423 | 25121797 |
US |
71 | 1 |
Product dose omission issue, Sinus disorder, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 424 | 25121835 |
US |
2 | |
Product dose omission issue, Product use issue, |
||||
MEPOLIZUMAB, |
||||
| 425 | 25121861 |
US |
41 | 1 |
Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND LAMIVUDINE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, BUPROPION HYDROCHLORIDE, BUPROPION, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, |
||||
| 426 | 25121876 |
US |
80 | 2 |
Pruritus, Product dose omission issue, |
||||
OMALIZUMAB, |
||||
| 427 | 25121953 |
US |
2 | |
Tremor, Product dose omission issue, Off label use, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 428 | 25121972 |
US |
49 | 2 |
Product dose omission issue, Depression, |
||||
PEGINTERFERON BETA-1A, |
||||
| 429 | 25122222 |
US |
72 | 1 |
Insomnia, Product dose omission issue, |
||||
CLADRIBINE, |
||||
| 430 | 25122238 |
US |
2 | |
Feeding disorder, Incorrect dose administered, Product dose omission issue, |
||||
TROFINETIDE, |
||||
| 431 | 25122283 |
US |
33 | 1 |
Colitis ulcerative, Drug hypersensitivity, Drug ineffective, Product dose omission issue, Off label use, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 432 | 25122308 |
US |
72 | 1 |
Needle issue, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 433 | 25122358 |
US |
||
Norovirus infection, Product dose omission issue, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 434 | 25122365 |
US |
||
Product dose omission issue, Product delivery mechanism issue, |
||||
FLUTICASONE PROPIONATE, |
||||
| 435 | 25122368 |
US |
2 | |
Product use complaint, Product dose omission issue, |
||||
TROFINETIDE, |
||||
| 436 | 25122422 |
US |
35 | 1 |
Product dose omission issue, |
||||
CABOTEGRAVIR, CABOTEGRAVIR, CABOTEGRAVIR, |
||||
| 437 | 25122586 |
US |
1 | |
Product dose omission issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 438 | 25122660 |
US |
32 | 1 |
Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE, |
||||
| 439 | 25122720 |
US |
78 | 2 |
Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 440 | 25122803 |
US |
2 | |
Product dose omission issue, Rash, Abdominal pain upper, |
||||
DIROXIMEL FUMARATE, ERGOCALCIFEROL, |
||||
| 441 | 25122829 |
US |
73 | 1 |
Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 442 | 25122843 |
US |
||
Groin abscess, Prostatic urethral lift procedure, Hypotension, Product dose omission issue, |
||||
RELUGOLIX, RELUGOLIX, VITAMIN A, ERGOCALCIFEROL, FISH OIL, IRON, NIACIN, DICLOFENAC, DICLOFENAC SODIUM, ISOSORBIDE DINITRATE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, CARVEDILOL, EZETIMIBE, LATANOPROST, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, SULFAMETHOXAZOLE AND TRIMETHOPRIM, |
||||
| 443 | 25122853 |
US |
2 | |
Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 444 | 25122959 |
US |
69 | 2 |
Cataract, Device issue, Needle issue, Product leakage, Product dose omission issue, |
||||
GOLIMUMAB, GOLIMUMAB, |
||||
| 445 | 25122988 |
US |
70 | 2 |
Dizziness, Diarrhoea, Arthropathy, Product dose omission issue, |
||||
PACRITINIB, |
||||
| 446 | 25123052 |
US |
||
Macular degeneration, Visual impairment, Device delivery system issue, Product dose omission issue, |
||||
ABALOPARATIDE, CALCIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 447 | 25123058 |
US |
2 | |
Constipation, Product dose omission issue, |
||||
TROFINETIDE, |
||||
| 448 | 25123075 |
US |
39 | |
Product dose omission issue, |
||||
NIVOLUMAB, |
||||
| 449 | 25123271 |
US |
48 | 2 |
Nasal polyps, Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 450 | 25123294 |
US |
53 | 1 |
Peripheral swelling, Self-medication, Product dose omission issue, Pulmonary function test decreased, Illness, |
||||
EPINEPHRINE, ADRENALINUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 451 | 25123406 |
US |
2 | |
Bronchitis, Product dose omission issue, |
||||
EPINEPHRINE, ADRENALINUM, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, CEVIMELINE HYDROCHLORIDE, ALBUTEROL SULFATE, CYANOCOBALAMIN, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, DEXLANSOPRAZOLE, ARMODAFINIL, PIROXICAM, CALCIUM, ONDANSETRON HYDROCHLORIDE, RITUXIMAB, MAGNESIUM, AZELASTINE HYDROCHLORIDE, AZELASTINE, FAMOTIDINE, DESVENLAFAXINE SUCCINATE, RIZATRIPTAN BENZOATE, PRAMIPEXOLE DIHYDROCHLORIDE, |
||||
| 452 | 25123436 |
US |
2 | |
Product dose omission issue, Fatigue, Headache, Nasal congestion, |
||||
EPINEPHRINE, ADRENALINUM, AZELASTINE HYDROCHLORIDE, AZELASTINE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN DIHYDRATE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, CEFEPIME HYDROCHLORIDE, CEFEPIME, FAMOTIDINE, |
||||
| 453 | 25123518 |
US |
2 | |
Rash, Product dose omission issue, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, EPINEPHRINE, ADRENALINUM, LIDOCAINE 4%, MENTHOL 1%, LIDOCAINE 4% MENTHOL 1%, FUROSEMIDE, ALPRAZOLAM, ALBUTEROL SULFATE, IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE, OXYGEN, 0XYGEN, |
||||
| 454 | 25123520 |
US |
56 | 2 |
Illness, Dyspnoea, Pyrexia, Product dose omission issue, |
||||
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, EPINEPHRINE, ADRENALINUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, LEVOTHYROXINE SODIUM, BUDESONIDE, HYDROCHLOROTHIAZIDE, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALPRAZOLAM, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE INHALATION SPRAY, METHYLPREDNISOLONE, SERTRALINE HYDROCHLORIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, MELATONIN, GABAPENTIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, OXYGEN, 0XYGEN, MONTELUKAST SODIUM, MONTELUKAST, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, |
||||
| 455 | 25123543 |
US |
2 | |
Wheezing, Cough, Product dose omission issue, |
||||
SOMATROPIN, HYDROXYCHLOROQUINE SULFATE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ALBUTEROL SULFATE, HYDROCHLOROTHIAZIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, LEFLUNOMIDE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, |
||||
| 456 | 25123556 |
US |
36 | 1 |
Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND LAMIVUDINE, |
||||
| 457 | 25123572 |
US |
1 | |
Product dose omission issue, Breath sounds abnormal, Dyspnoea exertional, Cough, |
||||
APIXABAN, ALBUTEROL SULFATE, OXYGEN, 0XYGEN, FLUTICASONE PROPIONATE, AMITRIPTYLINE HYDROCHLORIDE, TIOTROPIUM BROMIDE, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS CAPSULES, EPINEPHRINE, ADRENALINUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SIMVASTATIN, |
||||
| 458 | 25123577 |
US |
1 | |
Product dose omission issue, Lung disorder, |
||||
EPINEPHRINE, ADRENALINUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE AND OLODATEROL, GABAPENTIN, HYDROCHLOROTHIAZIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 459 | 25123587 |
US |
67 | 1 |
Sinusitis, Upper-airway cough syndrome, Product dose omission issue, |
||||
ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, WARFARIN, |
||||
| 460 | 25123624 |
US |
1 | |
Vein rupture, Contusion, Product dose omission issue, |
||||
ALBUTEROL SULFATE, TIOTROPIUM BROMIDE INHALATION SPRAY, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 461 | 25123722 |
US |
||
Product dose omission issue, Product delivery mechanism issue, |
||||
FLUTICASONE PROPIONATE, |
||||
| 462 | 25123748 |
GR |
2 | |
Condition aggravated, Confusional state, Product dose omission issue, Product supply issue, |
||||
RIVASTIGMINE, |
||||
| 463 | 25123764 |
US |
||
Asthma, Product dose omission issue, |
||||
| 464 | 25123916 |
US |
2 | |
Tremor, Visual impairment, Memory impairment, Nervousness, Dizziness, Product dose omission issue, |
||||
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, DAPAGLIFLOZIN, TAFAMIDIS MEGLUMINE, APIXABAN, FUROSEMIDE, LISINOPRIL, SPIRONOLACTONE, |
||||
| 465 | 25124030 |
US |
50 | 1 |
Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 466 | 25124041 |
US |
55 | 1 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 467 | 25124056 |
US |
35 | 2 |
Eczema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 468 | 25124370 |
CA |
24 | 2 |
Urinary tract infection, Product dose omission issue, Intentional dose omission, |
||||
OFATUMUMAB, |
||||
| 469 | 25124399 |
US |
45 | 2 |
Pain, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 470 | 25124400 |
CA |
2 | |
Diabetes mellitus, Fatigue, Illness, Injection site discomfort, Drug ineffective, Product dose omission issue, Off label use, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 471 | 25124403 |
US |
||
No adverse event, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 472 | 25124510 |
US |
2 | |
Product dose omission issue, Device defective, |
||||
SECUKINUMAB, |
||||
| 473 | 25124573 |
US |
52 | 2 |
Illness, Nasopharyngitis, Cough, Pyrexia, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 474 | 25124607 |
US |
2 | |
Product dose omission issue, Gait inability, Joint dislocation, Gait disturbance, Fall, Depression, |
||||
NATALIZUMAB, |
||||
| 475 | 25124784 |
US |
68 | 1 |
Ileus, Product dose omission issue, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 476 | 25124858 |
US |
42 | 2 |
Blood test abnormal, Pain, Abdominal discomfort, Abdominal pain upper, Back pain, Abdominal pain, Constipation, Headache, Alanine aminotransferase increased, Underdose, Drug monitoring procedure not performed, Therapy interrupted, Product use issue, Product dose omission issue, Product prescribing issue, |
||||
TOLVAPTAN, TOLVAPTAN, TOLVAPTAN, TOLVAPTAN, TOLVAPTAN, |
||||
| 477 | 25124899 |
US |
63 | 1 |
Product dose omission issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 478 | 25124949 |
US |
42 | 1 |
Spinal operation, Product dose omission issue, |
||||
BRODALUMAB, BRODALUMAB, |
||||
| 479 | 25124976 |
US |
2 | |
Blood glucose increased, Product dose omission issue, |
||||
INSULIN GLARGINE, |
||||
| 480 | 25124979 |
US |
59 | 1 |
Accidental underdose, Product dose omission issue, |
||||
INSULIN GLARGINE, |
||||
| 481 | 25125105 |
US |
49 | 2 |
Nausea, Product dose omission issue, Intentional product use issue, |
||||
PACRITINIB, |
||||
| 482 | 25125174 |
US |
2 | |
Headache, Dizziness, Product dose omission issue, |
||||
ELAFIBRANOR, FENOFIBRATE, PANTOPRAZOLE, MILNACIPRAN HYDROCHLORIDE, URSODIOL, URSOSIOL, |
||||
| 483 | 25125295 |
US |
61 | 1 |
Product dose omission issue, Product leakage, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 484 | 25125459 |
63 | ||
Product dose omission issue, Product odour abnormal, |
||||
RUXOLITINIB, |
||||
| 485 | 25125485 |
US |
2 | |
Product dose omission issue, No adverse event, |
||||
| 486 | 25125578 |
US |
32 | 1 |
Hospitalisation, Suicide attempt, Self-destructive behaviour, Victim of sexual abuse, Thermal burn, Schizophrenia, Corneal abrasion, Hypersomnia, Product dose omission issue, Coma, Tardive dyskinesia, Weight decreased, Muscle atrophy, Gastrointestinal disorder, Hypotension, Overdose, Scoliosis, Intentional self-injury, Oesophageal ulcer, Oesophageal injury, Fractured coccyx, Gastrooesophageal reflux disease, Oesophageal haemorrhage, Gastric ulcer, Haematemesis, Adverse drug reaction, Pneumothorax, Acute oesophageal mucosal lesion, Allergic cough, Dehydration, Seasonal allergy, Exposure to fungus, Migraine, Hallucination, Auditory disorder, Upper limb fracture, Fall, |
||||
DIVALPROEX SODIUM, VALBENAZINE, VALBENAZINE, VALBENAZINE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, HYDROXYZINE, BENZTROPINE, OLANZAPINE, OLANZAPINE PAMOATE, LORATADINE, LORATADINE TABLET, ESCITALOPRAM, EMPAGLIFLOZIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PANTOPRAZOLE, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, ACETAMINOPHEN, ASPRIN, CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, CAFFEINE, LUMATEPERONE, OLANZAPINE AND SAMIDORPHAN L-MALATE, DUPILUMAB, PROPRANOLOL HYDROCHLORIDE, |
||||
| 487 | 25125596 |
US |
70 | 2 |
Injection site pain, Product dose omission issue, |
||||
DULAGLUTIDE, DULAGLUTIDE, |
||||
| 488 | 25125651 |
US |
76 | 1 |
Systemic infection, Product dose omission issue, Eye pain, |
||||
CENEGERMIN-BKBJ, CENEGERMIN-BKBJ, ERYTHROMYCIN, ACYCLOVIR, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, |
||||
| 489 | 25125665 |
CO |
53 | 2 |
Device deployment issue, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 490 | 25125695 |
US |
47 | 2 |
Device defective, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 491 | 25125701 |
PT |
||
Product packaging quantity issue, Product dose omission issue, |
||||
PEGVISOMANT, |
||||
| 492 | 25125736 |
US |
2 | |
Hospitalisation, Product dose omission issue, |
||||
VONOPRAZAN FUMARATE, FAMOTIDINE, ALLOPURINOL, FENOFIBRATE, |
||||
| 493 | 25125844 |
US |
67 | |
Product dose omission issue, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 494 | 25125863 |
US |
67 | 2 |
Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 495 | 25126022 |
CA |
1 | |
Palpitations, Rhinorrhoea, Lower respiratory tract congestion, Hyperaesthesia teeth, Illness, Product dose omission issue, Dizziness, Nausea, Blood pressure abnormal, |
||||
BIMEKIZUMAB, |
||||
| 496 | 25126028 |
US |
76 | 2 |
Rheumatoid arthritis, Product dose omission issue, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 497 | 25126034 |
US |
1 | |
Depression, Feeling abnormal, Poor quality sleep, Muscle atrophy, Product dose omission issue, Pain, Gait inability, Muscle spasms, Fatigue, Fluid intake reduced, |
||||
OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, OMAVELOXOLONE, BUPROPION HYDROCHLORIDE, BUPROPION, TIZANIDINE, MELOXICAM, |
||||
| 498 | 25126070 |
US |
5 | 2 |
Gastrointestinal disorder, Amylase increased, Lipase increased, Product dose omission issue, Nasopharyngitis, |
||||
GUSELKUMAB, |
||||
| 499 | 25126077 |
US |
||
Asthma, Product dose omission issue, Wrong technique in product usage process, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE AND BUDESONIDE, |
||||
| 500 | 25126110 |
US |
31 | 1 |
Product dose omission issue, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28